U.S. Markets closed

Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll show how Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E ratio could help you assess the value on offer. Based on the last twelve months, Eagle Pharmaceuticals's P/E ratio is 23.48. That corresponds to an earnings yield of approximately 4.3%.

View our latest analysis for Eagle Pharmaceuticals

How Do I Calculate A Price To Earnings Ratio?

The formula for P/E is:

Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Or for Eagle Pharmaceuticals:

P/E of 23.48 = $50.72 ÷ $2.16 (Based on the trailing twelve months to December 2018.)

Is A High P/E Ratio Good?

A higher P/E ratio means that buyers have to pay a higher price for each $1 the company has earned over the last year. All else being equal, it's better to pay a low price -- but as Warren Buffett said, 'It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.'

How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. Earnings growth means that in the future the 'E' will be higher. That means even if the current P/E is high, it will reduce over time if the share price stays flat. A lower P/E should indicate the stock is cheap relative to others -- and that may attract buyers.

Eagle Pharmaceuticals saw earnings per share decrease by 37% last year. But EPS is up 58% over the last 5 years.

How Does Eagle Pharmaceuticals's P/E Ratio Compare To Its Peers?

We can get an indication of market expectations by looking at the P/E ratio. You can see in the image below that the average P/E (19.7) for companies in the biotechs industry is lower than Eagle Pharmaceuticals's P/E.

NasdaqGM:EGRX Price Estimation Relative to Market, April 3rd 2019

Its relatively high P/E ratio indicates that Eagle Pharmaceuticals shareholders think it will perform better than other companies in its industry classification. Clearly the market expects growth, but it isn't guaranteed. So further research is always essential. I often monitor director buying and selling.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

Don't forget that the P/E ratio considers market capitalization. Thus, the metric does not reflect cash or debt held by the company. Theoretically, a business can improve its earnings (and produce a lower P/E in the future), by taking on debt (or spending its remaining cash).

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

How Does Eagle Pharmaceuticals's Debt Impact Its P/E Ratio?

The extra options and safety that comes with Eagle Pharmaceuticals's US$34m net cash position means that it deserves a higher P/E than it would if it had a lot of net debt.

The Verdict On Eagle Pharmaceuticals's P/E Ratio

Eagle Pharmaceuticals has a P/E of 23.5. That's higher than the average in the US market, which is 17.7. Falling earnings per share is probably keeping traditional value investors away, but the relatively strong balance sheet will allow the company time to invest in growth. Clearly, the high P/E indicates shareholders think it will!

Investors should be looking to buy stocks that the market is wrong about. As value investor Benjamin Graham famously said, 'In the short run, the market is a voting machine but in the long run, it is a weighing machine.' So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

But note: Eagle Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.